

Dawn R Cochrane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3125018/publications.pdf>

Version: 2024-02-01

23
papers

1,135
citations

567281

15
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

2674
citing authors

#	ARTICLE	IF	CITATIONS
1	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. <i>Cell</i> , 2018, 173, 1755-1769.e22.	28.9	261
2	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , 2017, 49, 856-865.	21.4	220
3	Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research. <i>Scientific Reports</i> , 2016, 6, 34949.	3.3	100
4	The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. <i>Molecular Carcinogenesis</i> , 2019, 58, 196-205.	2.7	91
5	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. <i>Journal of Pathology</i> , 2017, 243, 26-36.	4.5	69
6	TERT promoter mutation in adult granulosa cell tumor of the ovary. <i>Modern Pathology</i> , 2018, 31, 1107-1115.	5.5	49
7	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. <i>Oncotarget</i> , 2017, 8, 18949-18967.	1.8	47
8	Clear cell carcinomas of the ovary and kidney: clarity through genomics. <i>Journal of Pathology</i> , 2018, 244, 550-564.	4.5	41
9	Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. <i>Journal of Pathology</i> , 2019, 249, 319-331.	4.5	36
10	Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. <i>Journal of Pathology</i> , 2020, 252, 201-214.	4.5	31
11	APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. <i>Gynecologic Oncology</i> , 2017, 147, 663-671.	1.4	29
12	Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 243-252.	3.0	27
13	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020, 26, 4402-4413.	7.0	21
14	Napsin-A and AMACR are Superior to HNF-1 β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 593-601.	1.2	20
15	c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract. <i>American Journal of Surgical Pathology</i> , 2020, 44, 495-502.	3.7	16
16	Use of Immunohistochemical Markers (HNF-1 β , Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 344-353.	1.4	14
17	LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers. <i>Gynecologic Oncology</i> , 2017, 147, 642-647.	1.4	13
18	Modelling hereditary diffuse gastric cancer initiation using transgenic mouse-derived gastric organoids and single-cell sequencing. <i>Journal of Pathology</i> , 2021, 254, 254-264.	4.5	11

#	ARTICLE	IF	CITATIONS
19	FOXL2 in adult-type granulosa cell tumour of the ovary: oncogene or tumour suppressor gene?. Journal of Pathology, 2021, 255, 225-231.	4.5	10
20	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. Human Pathology, 2019, 92, 39-47.	2.0	9
21	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. Human Pathology, 2021, 108, 1-11.	2.0	8
22	<sc>STING</sc> pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?. Journal of Pathology: Clinical Research, 2021, 7, 548-555.	3.0	6
23	Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. Human Pathology, 2020, 101, 40-52.	2.0	4